Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Change in Cash (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Change in Cash for 11 consecutive years, with $17.3 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 142.03% to $17.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.2 million through Dec 2025, down 261.34% year-over-year, with the annual reading at -$6.2 million for FY2025, 261.34% down from the prior year.
  • Change in Cash hit $17.3 million in Q4 2025 for Voyager Therapeutics, up from $3.9 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $169.4 million in Q1 2023 to a low of -$179.0 million in Q3 2023.
  • Historically, Change in Cash has averaged -$1.9 million across 5 years, with a median of $3.5 million in 2023.
  • Biggest five-year swings in Change in Cash: crashed 119673.33% in 2022 and later skyrocketed 1072.87% in 2023.
  • Year by year, Change in Cash stood at $6.0 million in 2021, then crashed by 64.77% to $2.1 million in 2022, then surged by 68.32% to $3.5 million in 2023, then tumbled by 1264.96% to -$41.2 million in 2024, then surged by 142.03% to $17.3 million in 2025.
  • Business Quant data shows Change in Cash for VYGR at $17.3 million in Q4 2025, $3.9 million in Q3 2025, and -$30.8 million in Q2 2025.